Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center.

This letter to the editor discusses the treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center (MSKCC). The study included 19 patients who were treated with salvage regimens, and found no differences in response rates, progression-free survival, and overall survival between methotrexate re-challenge and non-methotrexate-based therapy. PCNSL is a rare and aggressive form of non-Hodgkin lymphoma that primarily affects the central nervous system. Refractory patients have a poor prognosis, and salvage regimens are recommended for treatment. The study found that a non-methotrexate salvage regimen was chosen more frequently for patients who received a higher number of methotrexate doses during induction, and salvage consolidation with autologous stem cell transplant was associated with good disease control and durable response. The MSKCC Prognostic Model score of I was associated with a better outcome. Further research is needed to differentiate response rates between specific salvage regimens and survival among patients who receive autologous stem cell transplant consolidation for methotrexate-refractory PCNSL. [Extracted from the article]

Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)